182 results
8-K
EX-10.1
TENX
Tenax Therapeutics Inc
20 Feb 24
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
8:33am
8-K
EX-10.1
TENX
Tenax Therapeutics Inc
12 Feb 24
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
4:46pm
8-K
EX-10.2
TENX
Tenax Therapeutics Inc
12 Feb 24
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
4:46pm
8-K
EX-10.1
kcbnfwua25nbrz m0
10 Feb 23
Termination of a Material Definitive Agreement
4:31pm
8-K
EX-10.1
3fpbyz1
7 Feb 23
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
4:31pm
8-K
EX-10.2
j51gn
7 Feb 23
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
4:31pm
8-K
EX-10.3
3xb5x6 g9
7 Feb 23
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
4:31pm
8-K
EX-10.1
tugbw56xi
16 Jun 22
Entry into a Material Definitive Agreement
4:35pm
8-K
EX-10.1
vy7c5s4ij
10 Jun 22
Departure of Directors or Certain Officers
4:31pm
8-K
EX-10.2
erbyj41
10 Jun 22
Departure of Directors or Certain Officers
4:31pm
8-K
EX-10.2
j7s i7qar9glmd8h34
20 May 22
Tenax Therapeutics Announces Certain Securities and Nasdaq Disclosures
4:30pm
8-K
EX-10.1
62t0gwbvzsfqlsni8
20 May 22
Tenax Therapeutics Announces Certain Securities and Nasdaq Disclosures
4:30pm
8-K
EX-10.1
ryey027icy4
28 Jan 22
Entry into a Material Definitive Agreement
4:16pm